ArunA has built a comprehensive intellectual property portfolio encompassing key aspects of exosome-based therapeutics.

Coupled with proprietary manufacturing methods, the company is set to develop transformational therapeutics across a range of CNS and neurodegenerative disorders.

We are actively seeking partnerships in the stroke and neural degenerative disease space, and also seeking partners in drug delivery and gene therapy.

Why ArunA?

  • Novel non-cellular biologic approach

  • Exploiting complex pathophysiologic pathways to address acute and chronic neurologic conditions

  • Proven neural protection and anti-inflammatory activity

  • Poised to advance multiple indications into clinical development

  • Consistent, scalable exosome manufacturing process

  • Strong science platform with continuing leadership by Dr. Steven Stice

  • Treatment greatly reduces hemorrhaging within 24 hours post injury

To discuss a potential partnership with ArunA, please contact Al Medwar at